Iscover (Clopidogrel)

• Clopidogrel is used to prevent thrombotic cardiovascular events by inhibiting platelet aggregation in several clinical settings.
• Prevention of atherothrombotic events: reduces recurrence of myocardial infarction, ischemic stroke and peripheral arterial disease complications in patients with prior events.
• Acute coronary syndrome: helps limit further clot formation during unstable angina or myocardial infarction, supporting early medical management.
• Post‑percutaneous coronary intervention: lowers the risk of stent thrombosis after PCI, contributing to long‑term vessel patency.

• Clopidogrel is a pro‑drug metabolized in the liver to an active thiol metabolite that binds irreversibly to the P2Y12 ADP receptor on platelets. This blocks ADP‑mediated activation of the GPIIb/IIIa complex, preventing the final common pathway of platelet aggregation and providing sustained antithrombotic effect for the platelet’s lifespan.

Clopidogrel may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Bleeding gums or easy bruising
• Nausea or abdominal discomfort
• Headache or dizziness
• Diarrhea

Serious or Rare Side Effects

• Severe or uncontrolled bleeding, including intracranial hemorrhage
• Thrombotic thrombocytopenic purpura (TTP)
• Allergic reactions such as rash, pruritus or angioedema

When prescribing clopidogrel, clinicians should consider several precautionary measures to ensure safe use.

• Assess bleeding risk: evaluate history of gastrointestinal ulcers, hemorrhagic disorders or recent surgery.
• Monitor platelet function: periodic laboratory testing may be needed in patients with unexplained bleeding.
• Avoid concomitant use with other antiplatelet or anticoagulant agents unless clinically justified.
• Renal or hepatic impairment: dose adjustment may be required based on physician assessment.
• Pregnancy and lactation: use only if potential benefit outweighs potential risk to fetus or infant.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Clopidogrel can interact with several medicines, altering its antiplatelet activity or increasing bleeding risk.

Major Interactions (Avoid)

• Strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): may reduce conversion to active metabolite, decreasing efficacy.
• Concurrent use of oral anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increases bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) at high doses: potentiate gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors with weaker CYP2C19 inhibition (e.g., pantoprazole): may modestly affect activation.
• Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: can increase bleeding tendency.
• Statins metabolized by CYP3A4 (e.g., atorvastatin): potential for modest pharmacokinetic interaction.